In addition to the two metastatic ER+ breast cancer trials, we also evaluated the performance of the signatures in the ACOSOG Z1031B clinical trial which evaluated neoadjuvant aromatase inhibitor (AI) treatment in Stage II or III ER+ breast cancers (Ellis et al, 2017). Here, CYP19A1 is linked to breast carcinoma.